[1] Liu D,Ha C,Zhang X,et al.Molecular implication of ADAM-15 and 17 in intrauterine adhesions[J].Eur J Obs Gynecol Reprod Biol,2013,170(1):264-269. [2] Tillmanns TD,Lowe MP,Walker MS,et al.Phase Ⅱ clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent,platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma[J].Gynecol Oncol,2013,128(2):221-228. [3] 俊杰,赵俊玲,孙建业,等.CT引导下放射性碘粒子植入联合化疗对中晚期胰腺癌的疗效[J].介入放射学杂志,2015,24(6):494-497. [4] 丁婕,戴旭,孟宪运,等.实体瘤疗效评价标准的研究进展明[J].中国肿瘤临床与康复,2015,22(9):1150-1152. [5] 马丽芳,周琦,李蓉.贝伐单抗联合化疗对铂敏感型复发性卵巢癌的近期疗效及安全性研究[J].重庆医学,2017,46(4):1532-1535. [6] 孙东斌.贝伐单抗联合白蛋白结合型紫杉醇治疗复发性卵巢癌的临床观察[J].实用癌症杂志,2017,32(5):823-826. [7] 王营,郭志,张炜浩,等.CT引导下125I粒子植入联合化疗治疗复发性卵巢癌[J].中国肿瘤临床,2015,42(2):87-90. [8] 姜靖,邓晓阳,胡晓蕙.CA125、CA199 和CEA联合检测在卵巢癌诊断中的临床意义[J].中国实验诊断学,2014,18(7):1145-1148. [9] G siorowska E, Michalak M, Warcho W, et al. Clinical application of HE4 and CA125 in ovarian cancer type Ⅰ and type Ⅱ detection and differential diagnosis[J].Ginekol Pol,2015, 86(2):88-93.
2019, Vol. 36 
